- Home
- AISP vs ZNTL Comparison
AISP vs ZNTL Comparison
Compare AISP & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AISP
- ZNTL
- Stock Information
- Founded
- AISP 2006
- ZNTL 2014
- Country
- AISP United States
- ZNTL United States
- Employees
- AISP N/A
- ZNTL N/A
- Industry
- AISP Blank Checks
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- AISP Finance
- ZNTL Health Care
- Exchange
- AISP Nasdaq
- ZNTL Nasdaq
- Market Cap
- AISP 107.6M
- ZNTL 102.2M
- IPO Year
- AISP N/A
- ZNTL 2020
- Fundamental
- Price
- AISP $5.15
- ZNTL $1.21
- Analyst Decision
- AISP Strong Buy
- ZNTL Buy
- Analyst Count
- AISP 1
- ZNTL 9
- Target Price
- AISP $6.00
- ZNTL $8.69
- AVG Volume (30 Days)
- AISP 1.2M
- ZNTL 689.9K
- Earning Date
- AISP 05-15-2025
- ZNTL 05-14-2025
- Dividend Yield
- AISP N/A
- ZNTL N/A
- EPS Growth
- AISP N/A
- ZNTL N/A
- EPS
- AISP N/A
- ZNTL N/A
- Revenue
- AISP $17,978,226.00
- ZNTL $26,865,000.00
- Revenue This Year
- AISP $34.30
- ZNTL N/A
- Revenue Next Year
- AISP $59.47
- ZNTL N/A
- P/E Ratio
- AISP N/A
- ZNTL N/A
- Revenue Growth
- AISP N/A
- ZNTL N/A
- 52 Week Low
- AISP $1.90
- ZNTL $1.01
- 52 Week High
- AISP $7.66
- ZNTL $13.00
- Technical
- Relative Strength Index (RSI)
- AISP 59.86
- ZNTL 42.23
- Support Level
- AISP $5.05
- ZNTL $1.18
- Resistance Level
- AISP $5.59
- ZNTL $1.27
- Average True Range (ATR)
- AISP 0.44
- ZNTL 0.07
- MACD
- AISP 0.06
- ZNTL 0.01
- Stochastic Oscillator
- AISP 66.13
- ZNTL 30.30
About AISP Airship AI Holdings Inc.
Airship AI Holdings Inc is a robust AI-driven data management platform that solves complex data challenges for large institutions operating in dynamic and mission-critical environments with rapidly increasing volumes of data being ingested from a similarly rapidly growing number of data sources. Its primary offerings include Outpost AI, Acropolis, and Airship Command. Its offerings allow customers to manage their data across the full data lifecycle, when and where they need it, using a highly secure permission-based architecture.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.